KRT10 (Gene)

Organism:

Homo sapiens

Synonyms:BCIE, BIE, CK10, EHK, ENTREZ:3858, HGNC:6413, K10, KPP, KRT10, MIM:148080, NM_000421, NM_001379366, NP_000412, NP_001366295, keratin 10

Omim:OMIM:148080

Id:ENSG00000186395

Hgnc:HGNC:6413

Entrez:3858

Ensembl:ENSG00000186395

Description:keratin 10

This gene encodes a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. This gene is located within a cluster of keratin family members on chromosome 17q21. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View KRT10's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with KRT10.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using KRT10.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for KRT10.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with KRT10.

Results found

Linked to

	Label	Description
	GSE208634 1 V 2 DOXYCYCLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 14 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 3 V 5 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 9 V 13 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 5 V 4 VERTEPORFIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE137325 2 V 0 COPANLISIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE140322 0 V 2 IMATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 verteporfin 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE198982,GSE198986 1 V 2 DAUNORUBICIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273,GSE216292 14 V 1 PALBOCICLIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE208634 1 V 2 DOXYCYCLINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 14 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE135350 3 V 5 DEXAMETHASONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE213588 9 V 13 TRAMETINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE151090 5 V 4 VERTEPORFIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE137325 2 V 0 COPANLISIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE140322 0 V 2 IMATINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE151090 verteporfin 2 v 4 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE198982,GSE198986 1 V 2 DAUNORUBICIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE216273,GSE216292 14 V 1 PALBOCICLIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.